Product: Galectin 1 Antibody
Catalog: DF2383
Description: Rabbit polyclonal antibody to Galectin 1
Application: WB IHC IF/ICC
Cited expt.: IHC, IF/ICC
Reactivity: Human, Mouse, Rat
Prediction: Bovine, Horse, Sheep, Dog
Mol.Wt.: 14kDa; 15kD(Calculated).
Uniprot: P09382
RRID: AB_2839591

View similar products>>

   Size Price Inventory
 100ul $280 In stock
 200ul $350 In stock

Lead Time: Same day delivery

For pricing and ordering contact:
Local distributors

Product Info

Source:
Rabbit
Application:
WB 1:500-1:2000, IF/ICC 1:100-1:500, IHC 1:50-1:200
*The optimal dilutions should be determined by the end user. For optimal experimental results, antibody reuse is not recommended.
*Tips:

WB: For western blot detection of denatured protein samples. IHC: For immunohistochemical detection of paraffin sections (IHC-p) or frozen sections (IHC-f) of tissue samples. IF/ICC: For immunofluorescence detection of cell samples. ELISA(peptide): For ELISA detection of antigenic peptide.

Reactivity:
Human,Mouse,Rat
Prediction:
Bovine(100%), Horse(86%), Sheep(100%), Dog(86%)
Clonality:
Polyclonal
Specificity:
Galectin 1 Antibody detects endogenous levels of total Galectin 1.
RRID:
AB_2839591
Cite Format: Affinity Biosciences Cat# DF2383, RRID:AB_2839591.
Conjugate:
Unconjugated.
Purification:
The antiserum was purified by peptide affinity chromatography using SulfoLink™ Coupling Resin (Thermo Fisher Scientific).
Storage:
Rabbit IgG in phosphate buffered saline, pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol. Store at -20 °C. Stable for 12 months from date of receipt.
Alias:

Fold/Unfold

14 kDa laminin-binding protein; 14 kDa lectin; Beta galactoside binding lectin; Beta galactoside binding lectin L 14 I; beta galactoside binding protein; Beta-galactoside-binding lectin L-14-I; DKFZp686E23103; Gal 1; Gal-1; GAL1; Galaptin; Galbp; Galectin; Galectin-1; Galectin1; GBP; HBL; HLBP14; HPL; L 14.5; L-14.5; L14; Lactose binding lectin 1; Lactose-binding lectin 1; Lect14; Lectin galactoside binding soluble 1; Lectin galactoside-binding soluble 1; LEG1_HUMAN; LGALS 1; LGALS1; Lgals1 lectin galactose binding soluble 1; MAPK activating protein MP12; Putative MAPK activating protein MP12; Putative MAPK-activating protein PM12; S Lac lectin 1; S-Lac lectin 1;

Immunogens

Immunogen:

A synthesized peptide derived from human Galectin 1, corresponding to a region within the internal amino acids.

Uniprot:
Gene(ID):
Expression:
P09382 LEG1_HUMAN:

Expressed in placenta, maternal decidua and fetal membranes. Within placenta, expressed in trophoblasts, stromal cells, villous endothelium, syncytiotrophoblast apical membrane and villous stroma. Within fetal membranes, expressed in amnion, chorioamniotic mesenchyma and chorion (at protein level). Expressed in cardiac, smooth, and skeletal muscle, neurons, thymus, kidney and hematopoietic cells.

Sequence:
MACGLVASNLNLKPGECLRVRGEVAPDAKSFVLNLGKDSNNLCLHFNPRFNAHGDANTIVCNSKDGGAWGTEQREAVFPFQPGSVAEVCITFDQANLTVKLPDGYEFKFPNRLNLEAINYMAADGDFKIKCVAFD

Predictions

Predictions:

Score>80(red) has high confidence and is suggested to be used for WB detection. *The prediction model is mainly based on the alignment of immunogen sequences, the results are for reference only, not as the basis of quality assurance.

Species
Results
Score
Bovine
100
Sheep
100
Horse
86
Dog
86
Rabbit
71
Pig
0
Xenopus
0
Zebrafish
0
Chicken
0
Model Confidence:
High(score>80) Medium(80>score>50) Low(score<50) No confidence

Research Backgrounds

Function:

Lectin that binds beta-galactoside and a wide array of complex carbohydrates. Plays a role in regulating apoptosis, cell proliferation and cell differentiation. Inhibits CD45 protein phosphatase activity and therefore the dephosphorylation of Lyn kinase. Strong inducer of T-cell apoptosis.

Subcellular Location:

Secreted>Extracellular space>Extracellular matrix.

Extracellular region or secreted Cytosol Plasma membrane Cytoskeleton Lysosome Endosome Peroxisome ER Golgi apparatus Nucleus Mitochondrion Manual annotation Automatic computational assertionSubcellular location
Tissue Specificity:

Expressed in placenta, maternal decidua and fetal membranes. Within placenta, expressed in trophoblasts, stromal cells, villous endothelium, syncytiotrophoblast apical membrane and villous stroma. Within fetal membranes, expressed in amnion, chorioamniotic mesenchyma and chorion (at protein level). Expressed in cardiac, smooth, and skeletal muscle, neurons, thymus, kidney and hematopoietic cells.

References

1). Dihydroartemisinin inhibits galectin-1-induced ferroptosis resistance and peritoneal metastasis of gastric cancer via the Nrf2-HO-1 pathway. Phytomedicine : international journal of phytotherapy and phytopharmacology, 2025 (PubMed: 41166905) [IF=6.7]

Application: IHC    Species: human    Sample: GC tissues

Fig. 1. Galectin-1 plays a critical role in GCPM. (A) Representative images of H&E staining and galectin-1 IHC in GC tissues from patients with or without PM. (B) IRS scores of galectin-1 expression in GC tissues from patients with or without PM(n = 132). (C) Data from the GEPIA database showing the expression levels of LGALS1 in GC tissues compared with normal tissues. (D) The TIMER database illustrates LGALS1 expression in tumour and adjacent normal tissues. GEPIA data further indicate that LGALS1 expression correlates with the detailed clinical stage (E) and gross tumour stage (F) of GC. The Kaplan–Meier survival analysis demonstrates the associations between LGALS1 expression and the first-progression survival (G), postprogression survival (H), and overall survival (I) of GC patients. (J) A representative image showing the GCPM model using HGC-27 cells with different levels of galectin-1 expression. (K) Statistical analysis of the number of peritoneal metastatic nodules across the experimental groups. (L) H&E staining confirmed that the peritoneal nodules were adenocarcinoma tissue(400 × magnification). WT: Wild Type; NS: not statistically significant

Application: IF/ICC    Species: human    Sample: HGC-27 cells

Fig. 2. Galectin-1 increases the proliferation, invasion, and migration of GC cells. Representative images of PI/calcein staining in HGC-27 (A) and SGC-7901 (B) cell lines with varying levels of galectin-1 expression(200 × magnification). (C) Quantitative analysis of live cell proportions in all experimental groups by PI/calcein-AM staining. Representative images of EdU-stained HGC-27 (D) and SGC-7901 (E) cells with different galectin-1 expression levels(200 × magnification). (F) Quantification of EdU-positive cells in the various groups.(G)Representative images illustrating the migratory and invasive capacities of GC cells with altered galectin-1 expression(200 × magnification). (H) Statistical analyses of the number of migrated and invaded cells, respectively. (I)Representative images from colony formation assays performed in HGC-27 and SGC-7901 cells. (J) Quantitative results of colony-forming units for HGC-27 and SGC-7901 cells, respectively. WT: Wild Type; NS: not statistically significant

2). Establishment of papillary thyroid cancer organoid lines from clinical specimens. Frontiers in Endocrinology, 2023 (PubMed: 36992805) [IF=3.9]

Application: IF/ICC    Species: Mouse    Sample:

Figure 4 Immunofluorescence staining of CK19, Gal-1, Gal-3, and Ki-67 on PTC- and NTG-derived organoids and the matched tumor tissues. Nuclei were counterstained with DAPI (blue). Passage numbers of these organoid lines were: PTC-3_O, P3; PTC-10_O, P5; NTG-1_O, P4. CK19, Cytokeratin 19; Gal-1, Galectin-1; Gal-3, Galectin-3; NTG, nodular thyroid goiter; T, tumor; O, organoid. Scale bar, 100 µm.

Restrictive clause

 

Affinity Biosciences tests all products strictly. Citations are provided as a resource for additional applications that have not been validated by Affinity Biosciences. Please choose the appropriate format for each application and consult Materials and Methods sections for additional details about the use of any product in these publications.

For Research Use Only.
Not for use in diagnostic or therapeutic procedures. Not for resale. Not for distribution without written consent. Affinity Biosciences will not be held responsible for patent infringement or other violations that may occur with the use of our products. Affinity Biosciences, Affinity Biosciences Logo and all other trademarks are the property of Affinity Biosciences LTD.